NPPB and hydrops fetalis: The first, reported in the recent NorthStar trial [4], assessed whether high-risk but stable chronic HF patients, identified as those with NT-proBNP levels >1000 pg/mL, would benefit from prolonged specialized HF clinic assistance compared to referral back to general practitioners, and demonstrated no differences in the composite of mortality and hospitalization for cardiac causes, suggesting that the basal value of cardiac peptides has limited value to select out of hospital management strategy in HF patients.